The Trendlines Group (Trendlines) (SGX:42T
) announced that its portfolio company, IBI Ag, successfully completed its proof of concept (POC) for the AI-driven platform for De Novo design of novel bioinsecticide proteins.
“By leveraging cutting-edge AI technology and proprietary biological data, IBI Ag has developed a novel approach to computationally design bioinsecticide proteins that selectively and effectively target pests while aiming to minimize the impact on beneficial insects and the environment,” Trendlines says.
Trendlines adds that the De Novo design opens up many new markets by targeting insect challenges that were previously unattainable with naturally occurring proteins, while also optimizing commercial aspects such as higher gross margins, longer shelf life, stability, and resiliency.
“This advancement not only demonstrates our commitment to sustainability but also supports farmers in achieving higher yields without compromising the health of ecosystems,” says Arnon Heyman, IBI Ag’s CEO.
“IBI Ag’s achievement underscores the strength, depth and significant market potential of the Trendlines portfolio,” adds Haim Brosh, Trendlines’ CEO.
Shares in Trendlines closed 0.1 cent higher, or 1.92% up at 5.3 cents on March 12.
